KIF20A and familial pancreatic carcinoma: In addition to paprotrain, a vaccine against peptides derived from KIF20A has also been used in a recent phase I immunotherapy clinical trial for advanced pancreatic cancer.37 In line with our findings, cells treated with paprotrain also accumulate at metaphase and anaphase and display an increased percentage of monopolar as well as multipolar spindles.38, 39 Interestingly, paprotrain has also been shown to inhibit tumour angiogenesis and development, independent of its mitotic function.40